Seregard S, Kock E
Division of Ophthalmic Pathology and Oncology, S:t Erik's Eye Hospital, Stockholm, Sweden.
Acta Ophthalmol (Copenh). 1992 Jun;70(3):289-96. doi: 10.1111/j.1755-3768.1992.tb08566.x.
Clinical information, follow-up and histopathological parameters of the primary lesions were assessed for all (45) individuals with conjunctival malignant melanomas in Sweden presenting during a 22.5 year period (1969 to mid 1991). The annual incidence of conjunctival malignant melanoma in Sweden was 0.0240 per 100,000. On average, two new cases were diagnosed each year (population 8.6 million in 1991). Sixty-two per cent of the lesions recurred, but re-growth in itself was not correlated to reduced survival. The actuarial 10-year survival proportion using life-table analysis was 70%. A significantly reduced survival due to tumour-related death was noted in patients with tumours with high mitotic indices, many epithelioid cells and in lesions exceeding 10 mm in diameter. Other factors that may influence survival are presented in the context of previous reports. The present policy in Sweden for treating patients with malignant melanoma of the conjunctiva is outlined and discussed.
对瑞典在22.5年期间（1969年至1991年年中）出现的所有45例结膜恶性黑色素瘤患者的临床信息、随访情况和原发灶的组织病理学参数进行了评估。瑞典结膜恶性黑色素瘤的年发病率为每10万人0.0240例。平均每年诊断出两例新病例（1991年人口为860万）。62%的病变复发，但复发本身与生存率降低无关。使用生命表分析得出的10年精算生存率为70%。在有高有丝分裂指数、许多上皮样细胞的肿瘤患者以及直径超过10毫米的病变患者中，观察到与肿瘤相关死亡导致的生存率显著降低。在以往报告的背景下，还介绍了其他可能影响生存的因素。概述并讨论了瑞典目前治疗结膜恶性黑色素瘤患者的政策。
